Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F15%3A33151064" target="_blank" >RIV/61989592:15110/15:33151064 - isvavai.cz</a>
Alternative codes found
RIV/61988987:17110/15:A1601FYC RIV/00216208:11150/15:10288628 RIV/00179906:_____/15:10288628 RIV/00064165:_____/15:10288628
Result on the web
<a href="http://dx.doi.org/10.1056/NEJMoa1411321" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1411321</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1411321" target="_blank" >10.1056/NEJMoa1411321</a>
Alternative languages
Result language
angličtina
Original language name
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Original language description
Background Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma. Methods We randomly assigned 792 patients with relapsed multiple myeloma to carfilzomib with lenalidomide and dexamethasone (carfilzomib group) or lenalidomide and dexamethasone alone (control group). The primary end point was progression-freesurvival. Results Progression-free survival was significantly improved with carfilzomib (median, 26.3 months, vs. 17.6 months in the control group; hazard ratio for progression or death, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P=0.0001). The median overall survival was not reached in either group at the interim analysis. The Kaplan-Meier 24-month overall survival rates were 73.3% and 65.0% in the carfilzomib and control groups, respectively (hazard ratio for death, 0.79; 95% C
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
New England Journal of Medicine
ISSN
0028-4793
e-ISSN
—
Volume of the periodical
372
Issue of the periodical within the volume
2
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
142-152
UT code for WoS article
—
EID of the result in the Scopus database
—